

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Harsh
<b>Date of last notice</b>	6 August 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	28 April 2023
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 260,000 Ordinary Shares</li> <li>2) 60,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Listed options
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	2) 60,000
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1) 260,000 Ordinary Shares</li> <li>2) Nil Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Listed options expired

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Ludvigson
<b>Date of last notice</b>	23 November 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	28 April 2023
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 545,000 Ordinary Shares</li> <li>2) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Listed options
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	2) 120,000
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	1) 545,000 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Listed options expired

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jovanka Naumoska
<b>Date of last notice</b>	26 April 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	28 April 2023
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 292,500 Ordinary Shares</li> <li>2) 60,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Listed options
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	2) 60,000
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	1) 292,500 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	IBXOA options expired

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Van Asten
<b>Date of last notice</b>	26 April 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	28 April 2023
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 613,125 Ordinary Shares</li> <li>2) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Listed options
<b>Number acquired</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	2) 120,000
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	1) 613,125 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	IBXOA options expired

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert Proulx
<b>Date of last notice</b>	23 November 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	28 April 2023 listed options 30 April 2023 performance rights
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 6,163,250 Ordinary Shares</li> <li>2) 5,000,000 Performance Rights</li> <li>3) 282,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>4) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>5) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>6) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ol>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Listed options and performance rights
<b>Number acquired</b>	Nil
<b>Number disposed</b>	2) 5,000,000 3) 282,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	1) 6,163,250 Ordinary Shares 2) 5,000,000 Performance Rights 3) Nil Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 4) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 5) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027) 6) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Listed options and performance rights expired.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.